MedTrace Logo

Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa

NCT00918255 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 154

Last updated 2011-05-09

Study results available
· View outcomes & findings →

Summary

This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.

Conditions

Interventions

BIOLOGICAL

adalimumab

Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters

DRUG

Placebo

Subcutaneous injection using prefilled syringe containing 0.8 milliliters

Sponsors & Collaborators

Principal Investigators

  • Martin Okun, MD, PhD · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2010-03-31
Completion
2010-11-30

Countries

  • United States
  • Denmark
  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00918255 on ClinicalTrials.gov